We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Office of Regulatory Affairs officially began its transition to a program-based structure May 15, including a new Office of Bioresearch Monitoring Operations that will work with each of the FDA’s product centers to ensure subject protection in clinical studies. Read More
Bangalore-based pharmaceutical company Strides Sashun, formerly known as Strides Arcolab, was recently cited by the FDA for quality problems with pills bound for U.S. markets. Read More
The Australian Therapeutic Goods Administration issued an industry guidance proposing to quickly approve certain types of low-risk variations to registered medicines without requiring evaluation, allowing sponsors to implement the changes immediately. Read More
Two-thirds of the way through fiscal year 2017, the FDA has received at least 877 ANDAs, passing fiscal 2016’s total of 852 and beating fiscal 2015’s total by more than 330 applications. Read More
The European Medicines Agency has decided to postpone the implementation of its Clinical Trials Regulation from October of next year to 2019 at the earliest, due to technical difficulties. Read More
A trio of individual pharmaceutical recalls swept through the industry last week, spotlighting a variety of formulation and quality control issues at major drugmakers. Read More
Nevada’s landmark plan requiring insulin manufacturers to disclose price information was signed into law last week, establishing a more targeted strategy compared to the broader price transparency legislation currently being pursued in other states. Read More